Drug-Induced Lung Toxicities: What the Intensivist Should Know?

Authors

  • A. Parrot Service de pneumologie, AP–HP, hôpitaux universitaires de l’Est-Parisien, Pôle TVAR, hôpital Tenon
  • A. Gibelin UPMC, université Paris-VI
  • T. Issoufaly Service de pneumologie, AP–HP, hôpitaux universitaires de l’Est-Parisien, Pôle TVAR, hôpital Tenon
  • G. Voiriot Service de réanimation et USC médico-chirurgicale, AP–HP, hôpitaux universitaires de l’Est-Parisien, Pôle TVAR, hôpital Tenon
  • M. Djibré Service de réanimation et USC médico-chirurgicale, AP–HP, hôpitaux universitaires de l’Est-Parisien, Pôle TVAR, hôpital Tenon
  • J.M. Naccache Service de pneumologie, AP–HP, hôpitaux universitaires de l’Est-Parisien, Pôle TVAR, hôpital Tenon
  • J. Cadranel UPMC, université Paris-VI
  • M. Fartoukh UPMC, université Paris-VI

DOI:

https://doi.org/10.3166/rea-2018-0012

Abstract

Acute respiratory failure related to drug toxicity is challenging. Several drugs, also including targeted therapy and immunotherapy, have been reported to induce lung toxicity. Clinical and pathological presentations are heterogeneous suggesting different toxicity pulmonary mechanisms. Infection or pulmonary edema should be ruled out, and then drug-induced pneumonitis diagnosis should be considered. CT scan and bronchoscopy with bronchoalveolar lavage are helpful for the disease diagnosis. Due to the severity, the identified drug should be stopped and more frequently steroids should be started.

Published

2018-01-01

How to Cite

Parrot, A., Gibelin, A., Issoufaly, T., Voiriot, G., Djibré, M., Naccache, J., Cadranel, J., & Fartoukh, M. (2018). Drug-Induced Lung Toxicities: What the Intensivist Should Know?. Médecine Intensive Réanimation, 27(1), 45–56. https://doi.org/10.3166/rea-2018-0012

Most read articles by the same author(s)

1 2 > >>